theophylline has been researched along with Kidney Failure, Chronic in 31 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have studied the pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis, patients with chronic renal failure, and healthy subjects, and have assessed the predictive value of routine tests of liver function and renal function (creatinine clearance) for theophylline and enprofylline total body clearances." | 7.67 | The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ( de Jong, PE; de Zeeuw, RA; Ekman, I; Gips, CH; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1988) |
| "Theophylline, the bronchodilating agent, can cause life-threatening, generalized seizures when plasma concentrations exceed the usual therapeutic concentration range." | 7.67 | Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats. ( Levy, G; Ramzan, IM, 1987) |
| "Theophylline treatment was given to 11 patients." | 5.29 | Erythrocytosis after renal transplantation. The response to theophylline treatment. ( Dranitzki-Elhallel, M; Ilan, Y; Popovtzer, MM; Rubinger, D; Silver, J, 1994) |
| "Theophylline plasma levels and FEV1 were measured in patients affected by chronic obstructive pulmonary disease and a concomitant disease state (congestive heart failure, chronic cor pulmonale, obesity, peptic disease, hepatic cirrhosis, chronic renal failure) and treated with a sustained release theophylline preparation." | 5.06 | Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation. ( Dal Negro, R; Monici-Preti, P; Pomari, C; Turco, P, 1987) |
| "The clearance of theophylline by hemodialysis was determined in one patient who had polycystic kidney with chronic renal failure and bronchial asthma." | 3.68 | Clearance of theophylline by hemodialysis in one patient with chronic renal failure. ( Chang, DB; Kuo, SH; Luh, KT; Shen, FH; Yang, PC, 1992) |
| "In an exploratory study the 24-h urinary excretion pattern of caffeine and 14 of its major metabolites was studied in 32 volunteers (adults, adolescents and children), 14 patients either with end stage renal disease or liver cirrhosis, 7 heavy smokers and 27 patients on therapy with cimetidine, allopurinol, theophylline or phenytoin." | 3.68 | Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. ( Bircher, J; Brandes, A; Compagnone, D; Hille, H; Münch, B; Ullrich, D, 1992) |
| "We have studied the pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis, patients with chronic renal failure, and healthy subjects, and have assessed the predictive value of routine tests of liver function and renal function (creatinine clearance) for theophylline and enprofylline total body clearances." | 3.67 | The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. ( de Jong, PE; de Zeeuw, RA; Ekman, I; Gips, CH; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1988) |
| "Theophylline, the bronchodilating agent, can cause life-threatening, generalized seizures when plasma concentrations exceed the usual therapeutic concentration range." | 3.67 | Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats. ( Levy, G; Ramzan, IM, 1987) |
| "We examined renal function and Na+ balance in a patient with congestive heart failure who was treated with demeclocycline (DMC) on three separate occasions under strict metabolic balance conditions." | 3.67 | Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies. ( Braden, GL; Cox, M; Geheb, MA; Shook, A; Singer, I, 1985) |
| "Adenosine is a crucial mediator of contrast-induced nephropathy (CIN; an increase in serum creatinine of >or=0." | 2.71 | Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. ( Classen, M; Hennig, M; Huber, W; Ilgmann, K; Lutilsky, L; Page, M; Schipek, C; Schömig, A; Schweigart, U; Seyfarth, M; Valina, C; Wacker, A, 2003) |
| "Theophylline treatment was given to 11 patients." | 1.29 | Erythrocytosis after renal transplantation. The response to theophylline treatment. ( Dranitzki-Elhallel, M; Ilan, Y; Popovtzer, MM; Rubinger, D; Silver, J, 1994) |
| "In 43 ICU patients undergoing continuous volume constant hemofiltration (CVHF), the pharmacokinetics of 12 drugs were investigated to ensure correct dosage adjustments." | 1.28 | [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study]. ( Dehne, M; el Abed, K; Hofmann, W; Kroh, U; Lennartz, H, 1989) |
| "Theophylline half-life was reduced substantially during hemodialysis, 2." | 1.27 | Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis. ( Lee, CS; Marbury, TC; Peterson, JC, 1983) |
| " Hemodialysis accelerated theophylline elimination and shortened serum theophylline half-life in all patients (nondialysis t 1/2 = 7." | 1.26 | Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. ( Blair, AD; Cutler, RE; Delaney, CJ; Kradjan, WA; Martin, TR, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (48.39) | 18.7374 |
| 1990's | 9 (29.03) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 1 (3.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nigwekar, SU | 1 |
| Weiser, JM | 1 |
| Kalim, S | 1 |
| Xu, D | 1 |
| Wibecan, JL | 1 |
| Dougherty, SM | 1 |
| Mercier-Lafond, L | 1 |
| Corapi, KM | 1 |
| Eneanya, ND | 1 |
| Holbrook, EH | 1 |
| Brown, D | 1 |
| Thadhani, RI | 1 |
| Păunescu, TG | 1 |
| Hörl, WH | 1 |
| Tello, R | 1 |
| Huber, W | 2 |
| Schipek, C | 1 |
| Ilgmann, K | 2 |
| Page, M | 2 |
| Hennig, M | 2 |
| Wacker, A | 1 |
| Schweigart, U | 2 |
| Lutilsky, L | 2 |
| Valina, C | 1 |
| Seyfarth, M | 1 |
| Schömig, A | 1 |
| Classen, M | 2 |
| Ix, JH | 1 |
| McCulloch, CE | 1 |
| Chertow, GM | 1 |
| Dussol, B | 1 |
| Morange, S | 1 |
| Loundoun, A | 1 |
| Auquier, P | 1 |
| Berland, Y | 1 |
| Mazur, LI | 1 |
| Nikolaĭchik, VV | 1 |
| Astapenko, VG | 1 |
| Ostapenko, VA | 1 |
| Lee, CS | 1 |
| Peterson, JC | 1 |
| Marbury, TC | 1 |
| Bauer, LA | 1 |
| Bauer, SP | 1 |
| Blouin, RA | 1 |
| Kradjan, WA | 1 |
| Martin, TR | 1 |
| Delaney, CJ | 1 |
| Blair, AD | 1 |
| Cutler, RE | 1 |
| Ward, ME | 1 |
| Musa, MN | 1 |
| Bailey, L | 1 |
| Ilan, Y | 1 |
| Dranitzki-Elhallel, M | 1 |
| Rubinger, D | 1 |
| Silver, J | 1 |
| Popovtzer, MM | 1 |
| Vereerstraeten, A | 1 |
| Gastaldello, K | 1 |
| Gervy, C | 1 |
| Vanherweghem, JL | 1 |
| Tielemans, C | 1 |
| Arakawa, K | 1 |
| Suzuki, H | 1 |
| Naitoh, M | 1 |
| Matsumoto, A | 1 |
| Hayashi, K | 1 |
| Matsuda, H | 1 |
| Ichihara, A | 1 |
| Kubota, E | 1 |
| Saruta, T | 1 |
| Liebl, R | 1 |
| Krämer, BK | 1 |
| Erley, CM | 1 |
| Duda, SH | 1 |
| Rehfuss, D | 1 |
| Scholtes, B | 1 |
| Bock, J | 1 |
| Müller, C | 1 |
| Osswald, H | 1 |
| Risler, T | 1 |
| Jeschke, B | 1 |
| Weiss, W | 1 |
| Salmhofer, H | 1 |
| Briggs, WA | 1 |
| Levy, G | 3 |
| Gibson, TP | 1 |
| Whitman, W | 1 |
| Procknal, J | 1 |
| Chang, DB | 1 |
| Kuo, SH | 1 |
| Yang, PC | 1 |
| Shen, FH | 1 |
| Luh, KT | 1 |
| Ullrich, D | 1 |
| Compagnone, D | 1 |
| Münch, B | 1 |
| Brandes, A | 1 |
| Hille, H | 1 |
| Bircher, J | 1 |
| Hoffman, A | 1 |
| Kroh, U | 1 |
| Hofmann, W | 1 |
| Dehne, M | 1 |
| el Abed, K | 1 |
| Lennartz, H | 1 |
| Nicot, G | 1 |
| Charmes, JP | 1 |
| Lachatre, G | 1 |
| Sautereau, D | 1 |
| Valette, JP | 1 |
| Eichler, B | 1 |
| Leroux-Robert, C | 1 |
| Kraan, J | 1 |
| Jonkman, JH | 1 |
| Koëter, GH | 1 |
| Gips, CH | 1 |
| de Jong, PE | 1 |
| van der Mark, TW | 1 |
| Ekman, I | 1 |
| de Zeeuw, RA | 1 |
| Vree, TB | 1 |
| Martea, M | 1 |
| Tiggeler, RG | 1 |
| Hekster, YA | 1 |
| Hafkenscheid, JC | 1 |
| Nanji, AA | 1 |
| Greenway, DC | 1 |
| Dal Negro, R | 1 |
| Turco, P | 1 |
| Pomari, C | 1 |
| Monici-Preti, P | 1 |
| Vanholder, R | 1 |
| Van Landschoot, N | 1 |
| De Smet, R | 1 |
| Schoots, A | 1 |
| Ringoir, S | 1 |
| Ramzan, IM | 1 |
| Braden, GL | 1 |
| Geheb, MA | 1 |
| Shook, A | 1 |
| Singer, I | 1 |
| Cox, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Smell in Covid-19 and Efficacy of Nasal Theophylline[NCT04789499] | Phase 2 | 51 participants (Actual) | Interventional | 2021-03-15 | Completed | ||
| Efficacy of Oral Sodium Chloride vs iv Sodium Chloride in the Prevention of Contrast Nephropathy in Outpatients[NCT03476460] | Phase 2 | 269 participants (Actual) | Interventional | 2014-03-01 | Completed | ||
| Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial[NCT05283512] | 254 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The SF-36 is a well-established 36-item questionnaire evaluating physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. This test allows us to study the overall quality of life for those suffering from COVID-19 related OD. There is no single overall score for SF-36. The SF 36 generates 8 subscales with scores ranging from 0 (worst) to 100 (best). General health domain scores are reported here. (NCT04789499)
Timeframe: Baseline assessment
| Intervention | score on a scale (Median) |
|---|---|
| Theophylline | 75 |
| Placebo | 80 |
Questionnaire for Olfactory Dysfunction (QOD) assesses health-related quality of life of participants based on four factors such as eating, mental health, social interactions, or fear of dysfunction.. The survey also includes questions on parosmia, a phenomena of COVID-related OD. The QOD consists of 17 statements that participants score from 0-3, resulting in a total score from 0 to 51. Higher scores reflect better olfactory-specific QOL. (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline
| Intervention | score on a scale (Median) |
|---|---|
| Theophylline | 0.86 |
| Placebo | 1.43 |
The ODOR is a 28-item QOL instrument with a total score ranging from 0 to 112 points. Higher scores indicate worse QOL with higher degree of dysfunction and limitation. A decrease of 15 or more points is deemed to be a clinically significant improvement in QOL. (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups
| Intervention | score on a scale (Median) |
|---|---|
| Theophylline | -6.5 |
| Placebo | -4.5 |
"UPSIT 0-40 with higher scores indicating better smell.~This test is an objective, clinically validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching. Out of a total of 40 points, normosmia is defined as ≥34 for males and ≥35 for females, and an increase in ≥4 points will be deemed a clinically significant improvement in symptoms." (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline
| Intervention | score on a scale (Median) |
|---|---|
| Theophylline | 3 |
| Placebo | 0 |
"UPSIT 0-40 with higher scores indicating better results.~The response rate defined as the number of participants in each group self-reporting of at least slightly better improvement in the Clinical Global Improvement Scale at 6 weeks post intervention as compared to baseline, devided by the total number of participants in that specific group. The CGI-Improvement Scale has seven response options (from 1 as Very Much Improved to 7 as Very Much Worsened) for answers to the question Compared to your sense of smell before you started the nasal irrigations, how would you rate your sense of smell now . Participants reporting 3 as Minimally Improved, 2 as Much Improved, or 1 as Very Much Improved in the CGI-I will be deemed responders to treatment, and the rate of responders will be compared between the two arms." (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups
| Intervention | percentage of participants (Number) |
|---|---|
| Theophylline | 59 |
| Placebo | 43 |
4 reviews available for theophylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Contrast induced nephropathy].
Topics: Acetylcysteine; Acute Kidney Injury; Algorithms; Contrast Media; Creatinine; Critical Care; Fluid Th | 2009 |
Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis.
Topics: Aminophylline; Contrast Media; Creatinine; Humans; Kidney Diseases; Kidney Failure, Chronic; Randomi | 2004 |
Clinical pharmacokinetics of lithium.
Topics: Aged; Benzothiadiazines; Contraindications; Diuretics; Drug Interactions; Drug Monitoring; Female; H | 1994 |
[Complications after administration of contrast media in high-risk patients. Is a prophylactic dialysis meaningful?].
Topics: Atrial Natriuretic Factor; Calcium Channel Blockers; Contrast Media; Endothelin Receptor Antagonists | 1996 |
5 trials available for theophylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency.
Topics: Adenosine; Aged; Contrast Media; Coronary Angiography; Creatinine; Endpoint Determination; Female; H | 2003 |
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
Topics: Administration, Oral; Aged; Contrast Media; Creatinine; Diabetic Nephropathies; Diuretics; Drug Syne | 2006 |
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
Topics: Administration, Oral; Aged; Contrast Media; Creatinine; Diabetic Nephropathies; Diuretics; Drug Syne | 2006 |
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
Topics: Administration, Oral; Aged; Contrast Media; Creatinine; Diabetic Nephropathies; Diuretics; Drug Syne | 2006 |
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
Topics: Administration, Oral; Aged; Contrast Media; Creatinine; Diabetic Nephropathies; Diuretics; Drug Syne | 2006 |
Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline.
Topics: Acetylglucosaminidase; Adenosine; Aged; Combined Modality Therapy; Contrast Media; Creatinine; Doubl | 1999 |
Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study.
Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Contrast Media; Creatinine; Double-Blind Me | 2002 |
Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Digestive System Diseases; Heart Diseases; Hu | 1987 |
22 other studies available for theophylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
Characterization and Correction of Olfactory Deficits in Kidney Disease.
Topics: Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Olfaction Disorders; Phosphodiesterase I | 2017 |
Intrarenal kinetics: effect of adenosine and theophylline.
Topics: Adenosine; Contrast Media; Humans; Kidney Diseases; Kidney Failure, Chronic; Theophylline; Vasodilat | 2003 |
[Complications of extracorporeal hemosorption and their prevention].
Topics: Blood Coagulation; Calcium; Fever; Hemoperfusion; Heparin; Humans; Hypocalcemia; Kidney Failure, Chr | 1983 |
Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
Topics: Adult; Creatinine; Female; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; | 1983 |
The effect of acute and chronic renal failure on theophylline clearance.
Topics: Acute Kidney Injury; Female; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Theo | 1982 |
Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure.
Topics: Adult; Aged; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Metabolic Clearance Rate; Midd | 1982 |
Erythrocytosis after renal transplantation. The response to theophylline treatment.
Topics: Adult; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Peritonea | 1994 |
High haematocrit in haemodialysis patients can be controlled by theophylline administration.
Topics: Administration, Oral; Arteriovenous Shunt, Surgical; Erythropoietin; Hematocrit; Humans; Kidney Fail | 1994 |
Role of adenosine in the renal responses to contrast medium.
Topics: Adenosine; Animals; Calcium Channel Blockers; Contrast Media; Diltiazem; Dogs; Glomerular Filtration | 1996 |
Effect of cyclic nucleotides on mitogen. Responsiveness of lymphocytes from patients undergoing dialysis.
Topics: Bucladesine; Cyclic GMP; Drug Synergism; Humans; Kidney Failure, Chronic; Lectins; Lymphocyte Activa | 1978 |
Hemodialysis clearance of theophylline.
Topics: Asthma; Biotransformation; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Kidney Failur | 1977 |
Clearance of theophylline by hemodialysis in one patient with chronic renal failure.
Topics: Aminophylline; Asthma; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Theophyll | 1992 |
Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.
Topics: Adolescent; Adult; Age Factors; Allopurinol; Caffeine; Child; Cimetidine; Drug Interactions; Female; | 1992 |
Kinetics of drug action in disease states. XXXIX. Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure.
Topics: Animals; Blood Proteins; Charcoal; Hypnotics and Sedatives; Injections, Intravenous; Kidney Failure, | 1990 |
[Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study].
Topics: Adult; Aged; Cefotaxime; Ceftazidime; Digitoxin; Digoxin; Hemofiltration; Humans; Imipenem; Kidney F | 1989 |
Theophylline toxicity risks and chronic renal failure.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Kidney Failure, Chron | 1989 |
The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.
Topics: Adult; Aged; Bronchodilator Agents; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; | 1988 |
Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.
Topics: Aged; Humans; Kidney Failure, Chronic; Male; Peritoneal Dialysis, Continuous Ambulatory; Theophyllin | 1988 |
Falsely raised plasma theophylline concentrations in renal failure.
Topics: Biotransformation; Chromatography, High Pressure Liquid; False Positive Reactions; Humans; Immunoenz | 1988 |
Drug protein binding in chronic renal failure: evaluation of nine drugs.
Topics: Blood Proteins; Chromatography, High Pressure Liquid; Humans; Kidney Failure, Chronic; Pharmaceutica | 1988 |
Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats.
Topics: Animals; Brain; Disease Models, Animal; Female; Kidney Failure, Chronic; Protein Binding; Rats; Seiz | 1987 |
Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies.
Topics: Administration, Oral; Aldosterone; Animals; Anura; Biological Transport; Blood Urea Nitrogen; Body W | 1985 |